Compounds > pantoprazole sodium
Page last updated: 2024-11-12

pantoprazole sodium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID15008962
CHEMBL ID1200408
CHEBI ID50270
SCHEMBL ID3543

Synonyms (73)

Synonym
HMS3393L19
b-8610-23/sk&f-96022-z
rifun
pantecta
anagastra
b-8510-29
by-1023/sk&f-96022
inipomp
peptazol
apton
zurcal
ulcotenal
pantorc
dz-2352a
pantoprazole sodium
sodium 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}benzimidazol-1-ide
CHEBI:50270 ,
citrel
138786-67-1
MLS001424073
smr000469592
pantoprazole sodium salt
HMS2051L19
CHEMBL1200408
5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]benzimidazol-1-ide; sodium;pantoprazole sodium
A807440
tox21_302362
cas-138786-67-1
dtxsid7044215 ,
dtxcid5024215
NCGC00255835-01
tox21_112996
S4538 ,
AKOS015994677
CCG-100980
FT-0602602
NC00230
SCHEMBL3543
KS-1093
pantoprazole sodium;
5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole, sodium salt
J-516336
mfcd01658543
5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl) sulfinyl)-1h-benzimidazole sodium
HMS3715D12
sodium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
skf96022 sodium
FT-0673508
by-1023 sodium
sodium 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
pantoprazole sodium,(s)
sodium 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide
Q27122012
by1023 (sodium)
skf96022 (sodium)
SB17369
sodium 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl] benzimidazol-1-ide
pantoprazole sodium dr
sodium 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)benzimidazol-1-ide
pantoprazole sodium delayed-release
pantoprazole sodium sesquihydrate (ep monograph)
pantoprazole sodium d/r
pantoprazole sodiumdelayed-release
pantoprazole sodiumdr
protonixdelayed-release
protonixi.v.
pantoprazoel sodium
pantoprazole sodium (usp monograph)
pantoprazole sodium (usp impurity)
pantoprazole sodiumdelayed release
pantoprazole sodium (usp-rs)
pantoprazole sodium delayed release
pantoprazole sodium (mart.)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitorAn EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that inhibits H(+)/K(+)-exchanging ATPase, EC 3.6.3.10. Such compounds are also known as proton pump inhibitors.
anti-ulcer drugOne of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency33.49830.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency3.11290.000714.592883.7951AID1259369; AID1259392
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency27.47270.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency22.74250.001022.650876.6163AID1224838; AID1224893
pregnane X nuclear receptorHomo sapiens (human)Potency24.48510.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.98560.000229.305416,493.5996AID743069; AID743075; AID743078
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency55.27050.001019.414170.9645AID743191
aryl hydrocarbon receptorHomo sapiens (human)Potency9.18500.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency4.73080.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency19.44920.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency28.01010.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1209266Fraction unbound in jugular and femoral vein-cannulated lactating Sprague-Dawley rat serum at 0.4 mg/ml, iv administered as infusion after 8 hrs by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209274Drug uptake in jugular and femoral vein-cannulated lactating Sprague-Dawley rat milk at 0.4 mg/ml, iv administered as infusion after 8 hrs by LC-MS analysis in presence of GF1209182012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209267Fraction unbound in jugular and femoral vein-cannulated lactating Sprague-Dawley rat whole milk at 0.4 mg/ml, iv administered as infusion after 8 hrs by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209269Dissociation constant, pKa of the compound2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209270Drug uptake in jugular and femoral vein-cannulated lactating Sprague-Dawley rat serum at 0.4 mg/ml, iv administered as infusion after 2 hrs by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209273Drug uptake in jugular and femoral vein-cannulated lactating Sprague-Dawley rat milk at 0.4 mg/ml, iv administered as infusion after 8 hrs by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209275Asymmetrical efflux ratio of permeability in MDCK cells at 25 uM after 1 hr2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209268Ratio of unbound drug level in whole milk to skim milk in jugular and femoral vein-cannulated lactating Sprague-Dawley rat at 0.4 mg/ml, iv administered as infusion after 8 hrs by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209276Activity at rat ABCG2 expressed in MDCK cells assessed as asymmetrical efflux ratio of permeability at 25 uM after 1 hr2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1070215Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
AID1209265Ratio of drug level in milk to serum in jugular and femoral vein-cannulated lactating Sprague-Dawley rat at 0.4 mg/ml, iv administered as infusion2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209272Clearance in jugular and femoral vein-cannulated lactating Sprague-Dawley rat at 0.4 mg/ml, iv administered as infusion2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209264Protein binding in human serum2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209271Drug uptake in jugular and femoral vein-cannulated lactating Sprague-Dawley rat serum at 0.4 mg/ml, iv administered as infusion after 2 hrs by LC-MS analysis in presence of GF1209182012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1209263Ratio of drug level in milk to serum in jugular and femoral vein-cannulated lactating Sprague-Dawley rat at 0.4 mg/ml, iv administered as infusion in presence of GF1209182012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk.
AID1070214Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate after 40 mins by NMR spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amlodipine
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.		2.110dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound		antihypertensive agent;
calcium channel blocker;
vasodilator agent
chlordiazepoxide
Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.		2.110benzodiazepine
clomipramine
Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.		2.110dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		2.110C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nisoldipine
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.		2.110C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrendipine
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.		2.110C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		2.110aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
rabeprazole
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.		2.110benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
sulfinpyrazone
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.		2.110pyrazolidines;
sulfoxide		uricosuric drug
nicardipine hydrochloride
[no description available]		2.110dihydropyridinegeroprotector
nitazoxanide
nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug		2.110benzamides;
carboxylic ester
cefaclor anhydrous
Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		2.110cephalosporinantibacterial drug;
drug allergen
epigallocatechin gallate
epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.		2.110flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
tretinoin
Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.		2.110retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
mercaptopurine
Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.		2.110aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
isotretinoin
Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.		2.110retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
lu 19005
[no description available]		2.110
oxytetracycline hydrochloride
[no description available]		2.110
ConditionIndicatedRelationship StrengthStudiesTrials